# US 2026/0092036 A1 · Crystalline salts of a t-type calcium channel modulator and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092036 A1
- Document ID: US20260092036A1
- Status: Published application
- Kind: A1
- Application number: 19/311,030
- Filed: 2025-08-27
- Published: 2026-04-02
- Earliest claimed: 2023-03-02
- Assignees: Praxis Precision Medicines, Inc.
- Applicants: Praxis Precision Medicines, Inc.
- Inventors: Daniel Thomas Walters; Thomas San Ie
- Web page: https://patentgrep.com/patent/US20260092036A1

## CPC

- A61P 25/00: Drugs for disorders of the nervous system
- C07D 211/26: with hydrocarbon radicals, substituted by nitrogen atoms
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 25/16: Anti-Parkinson drugs
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides Pattern D, i.e., a crystalline form of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide hydrochloride salt trihydrate (Compound 1). The present disclosure also provides pharmaceutical compositions comprising Compound 1 in the form of Pattern D, as well as methods of treating neurological and psychiatric disorders by administering to a subject in need thereof Compound 1 in the form of Pattern D or a pharmaceutical composition comprising Compound 1 in the form of Pattern D.

## Claims

### Claim 1

A crystalline form of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide hydrochloride salt trihydrate (Compound 1) characterized by an x-ray powder diffraction (XRPD) pattern comprising at least one peak at the diffraction angle (° 2θ) selected from the group consisting of:
a peak at approximately 12.0°;
a peak at approximately 15.6°;
a peak at approximately 16.7°;
a peak at approximately 19.8°;
a peak at approximately 21.2°;
a peak at approximately 24.1°;
a peak at approximately 25.2°;
a peak at approximately 27.3°; and
a peak at approximately 30.2°.

### Claim 2 (depends on 1)

The crystalline form of claim 1 characterized by an XRPD pattern comprising the following peaks at the diffraction angle (° 2θ):
a peak at approximately 25.2°; and
a peak at approximately 27.3°.

### Claim 3 (depends on 1)

The crystalline form of claim 1 characterized by an XRPD pattern comprising the following peaks at the diffraction angle (° 2θ):
a peak at approximately 24.1°;
a peak at approximately 25.2°; and
a peak at approximately 27.3°.

### Claim 4 (depends on 1)

The crystalline form of claim 1 characterized by an XRPD pattern comprising the following peaks at the diffraction angle (° 2θ):
a peak at approximately 16.7°;
a peak at approximately 24.1°;
a peak at approximately 25.2°; and
a peak at approximately 27.3°.

### Claim 5 (depends on 1)

The crystalline form of claim 1 characterized by an XRPD pattern comprising the following peaks at the diffraction angle (° 2θ):
a peak at approximately 12.0°;
a peak at approximately 16.7°;
a peak at approximately 24.1°;
a peak at approximately 25.2°; and
a peak at approximately 27.3°.

### Claim 6 (depends on 1)

The crystalline form of claim 1 characterized by an XRPD pattern substantially the same as the XRPD pattern depicted in FIG. 2.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The crystalline form of any one of claims 1-6, wherein the crystalline form has a melting point onset as determined by differential scanning calorimetry (DSC) at about 75.2° C.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The crystalline form of any one of claims 1-7, wherein the crystalline form has a crystal structure characterized as a space group P1.

### Claim 9 (depends on 8)

The crystalline form of claim 8, wherein the crystal structure is characterized by an asymmetric unit cell with a volume of 1213.0(10) Å3 and 3-D parameters of a=8.584(3) Å; b=9.11(4) Å; c=17.043 Å.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A pharmaceutical composition comprising the crystalline form of any one of claims 1-8 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, further comprising a modified release-polymer.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the modified-release polymer is selected from the group consisting of a hydrophilic matrix polymer, a hydrophobic matrix polymer and a polyacrylate polymer.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the hydrophilic matrix polymer is hypromellose.

### Claim 14 (depends on 10, 11, 12, 13)

The pharmaceutical composition of any one of claims 10-13, wherein the pharmaceutical composition is for oral administration.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of treating a neurological disorder comprising administering to a subject in need thereof the crystalline form of any one of claims 1-9 or the pharmaceutical composition of any one of claims 10-14.

### Claim 16 (depends on 15)

The method of claim 15, wherein the neurological disorder is tremor.

### Claim 17 (depends on 16)

The method of claim 16, wherein the tremor is essential tremor, Parkinson's tremor, cerebellar tremor or CACNA1G tremor.

### Claim 18 (depends on 17)

The method of claim 17, wherein the tremor is essential tremor.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of treating a psychiatric disorder in a subject in need thereof, said method comprising administering to said subject the crystalline form of any one of claims 1-9 or the pharmaceutical composition of any one of claims 10-14.
